

Juris J Meier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189091/publications.pdf>

Version: 2024-02-01

169
papers

16,696
citations

13865

67
h-index

15732

125
g-index

183
all docs

183
docs citations

183
times ranked

12780
citing authors

#	ARTICLE	IF	CITATIONS
1	The incretin/glucagon system as a target for pharmacotherapy of obesity. <i>Obesity Reviews</i> , 2022, 23, .	6.5	26
2	Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 684-692.	4.4	6
3	Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.	4.4	0
4	Measurement of Gastric Emptying Using a ¹³ C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 751-757.	1.2	7
5	Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective. <i>Diabetes and Metabolism Journal</i> , 2022, , .	4.7	0
6	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <sc>PIONEER</sc> phase 3 programme. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1338-1350.	4.4	12
7	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2022, 13, 205-215.	2.5	5
8	Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1262-1272.	2.2	8
9	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	6.5	518
10	Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 479-488.	8.6	10
11	Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 360-370.	2.2	12
12	Another milestone in the evolution of GLP-1-based diabetes therapies. <i>Nature Medicine</i> , 2021, 27, 952-953.	30.7	3
13	Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. <i>Frontiers in Endocrinology</i> , 2021, 12, 645617.	3.5	42
14	Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2344-2353.	4.4	8
15	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.	11.4	121
16	Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 803-820.	3.6	75
17	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. <i>Peptides</i> , 2020, 125, 170176.	2.4	3
18	Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. <i>Diabetes Therapy</i> , 2020, 11, 305-318.	2.5	18

#	ARTICLE	IF	CITATIONS
19	Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 599-611.	4.4	10
20	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 699-704.	4.4	75
21	Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. <i>Diabetes Care</i> , 2020, 43, 2906-2909.	8.6	30
22	Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy. <i>Journal of Diabetes Science and Technology</i> , 2020, 15, 1932-2968/2097269.	2.2	3
23	Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin. <i>Diabetes Care</i> , 2020, 43, 2333-2335.	8.6	8
24	Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 2303-2312.	8.6	54
25	GLP-1 receptor agonists in type 1 diabetes: a MAGIC bullet?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 262-264.	11.4	13
26	SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?. <i>Endocrinology</i> , 2020, 161, .	2.8	1
27	Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2137-2145.	8.6	21
28	Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1263-1277.	4.4	68
29	Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2595-2605.	3.6	13
30	Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.	6.5	850
31	Characterization of Non-hormone Expressing Endocrine Cells in Fetal and Infant Human Pancreas. <i>Frontiers in Endocrinology</i> , 2019, 9, 791.	3.5	2
32	Importance of localization of insulinomas: a systematic analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 383-392.	2.6	15
33	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <i>Lancet, The</i> , 2019, 394, 39-50.	13.7	315
34	Pioneering oral peptide therapy for patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2019, 7, 500-502.	11.4	4
35	GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. <i>Diabetes</i> , 2019, 68, 897-900.	0.6	39
36	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 45.	3.5	94

#	ARTICLE	IF	CITATIONS
37	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1081-1087.	4.4	39
38	MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. <i>European Journal of Endocrinology</i> , 2019, 181, R211-R234.	3.7	156
39	The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. <i>Diabetes Mellitus</i> , 2019, 22, 461-466.	1.9	1
40	Incretin hormones: Their role in health and disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 5-21.	4.4	451
41	Adaptive changes in pancreas post Roux-Y gastric bypass induced weight loss. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3025.	4.0	15
42	Propensity score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100%U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2821-2829.	4.4	23
43	Basal rate tests (24-hour fasts) performed in type 1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: <sc>A</sc> randomized controlled prospective trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 783-790.	4.4	0
44	Impact of insulin glargine and lixisenatide on β -cell function in patients with type 2 diabetes mellitus: <sc>A</sc> randomized open-label study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1625-1629.	4.4	9
45	Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1327-1328.	4.4	17
46	A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. <i>Diabetic Medicine</i> , 2017, 34, 1165-1168.	2.3	5
47	Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 83-85.	11.4	10
48	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. <i>Circulation</i> , 2017, 136, 849-870.	1.6	415
49	Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 843-845.	11.4	2
50	Defects in β -Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. <i>Diabetes Care</i> , 2017, 40, 1314-1322.	8.6	21
51	Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 336-347.	4.4	194
52	A meta-analysis comparing clinical effects of short- or long-acting <sc>GLP</sc>-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 216-227.	4.4	123
53	Criteria for Determining Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasm Based on Computed Tomography. <i>Digestion</i> , 2016, 94, 230-239.	2.3	6
54	Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1253-1262.	4.4	13

#	ARTICLE	IF	CITATIONS
55	Impact of proton pump inhibitor treatment on pancreatic beta-cell area and beta-cell proliferation in humans. <i>European Journal of Endocrinology</i> , 2016, 175, 467-476.	3.7	2
56	Gastrointestinal safety of incretin therapies: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 630-632.	17.8	5
57	Incretin mimetics and insulin "closing the gap to normoglycaemia. <i>Nature Reviews Endocrinology</i> , 2016, 12, 689-690.	9.6	2
58	The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1. <i>Diabetologia</i> , 2016, 59, 966-969.	6.3	1
59	The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. <i>Lancet Diabetes and Endocrinology</i> ,the, 2016, 4, 525-536.	11.4	310
60	Abundance and turnover of GLP-1 producing L-cells in ileal mucosa are not different in patients with and without type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 84-91.	3.4	12
61	Differential expression of cell-cycle regulators in human beta-cells derived from insulinoma tissue. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 736-746.	3.4	9
62	Î²-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of Î²-Cell Dedifferentiation and Degranulation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 523-532.	3.6	107
63	Insulin Secretion. , 2016, , 546-555.e5.		3
64	Diabetes associated with pancreatic diseases. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 400-406.	2.3	35
65	Incretin-based therapies: where will we be 50 years from now?. <i>Diabetologia</i> , 2015, 58, 1745-1750.	6.3	39
66	Hyperglycemia Potentiates the Slowing of Gastric Emptying Induced by Exogenous GLP-1. <i>Diabetes Care</i> , 2015, 38, 1123-1129.	8.6	28
67	Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance. <i>Diabetologia</i> , 2015, 58, 1175-1182.	6.3	36
68	Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. <i>Critical Care</i> , 2015, 19, 20.	5.8	18
69	Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. <i>Diabetes Care</i> , 2015, 38, 1263-1273.	8.6	216
70	Studying Pancreatic Risks Caused by Incretin-Based Therapies. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 895-897.	2.2	4
71	Glucagon-Like Peptide 1 Attenuates the Acceleration of Gastric Emptying Induced by Hypoglycemia in Healthy Subjects. <i>Diabetes Care</i> , 2014, 37, 1509-1515.	8.6	32
72	Pancreatitis and incretin-based drugs: clarity or confusion?. <i>Lancet Diabetes and Endocrinology</i> ,the, 2014, 2, 92-93.	11.4	6

#	ARTICLE	IF	CITATIONS
73	Risk of pancreatitis in patients treated with incretin-based therapies. <i>Diabetologia</i> , 2014, 57, 1320-1324.	6.3	84
74	Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. <i>Diabetologia</i> , 2013, 56, 1878-1883.	6.3	36
75	Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 258-263.	4.4	16
76	Role of Reduced β -Cell Mass Versus Impaired β -Cell Function in the Pathogenesis of Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, S113-S119.	8.6	201
77	The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically Ill. <i>Diabetes Care</i> , 2013, 36, 3333-3336.	8.6	20
78	Diagnostic Accuracy of an α -Amended α -Insulin α -Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2012, 157, 767.	3.9	34
79	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2012, 8, 728-742.	9.6	971
80	Impaired Crosstalk between Pulsatile Insulin and Glucagon Secretion in Prediabetic Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E791-E795.	3.6	34
81	Inpatient Treatment of Type 2 Diabetes. <i>Deutsches A&#x0308;rzblatt International</i> , 2012, 109, 466-74.	0.9	15
82	Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. <i>Diabetologia</i> , 2012, 55, 1346-1354.	6.3	123
83	Long-term recovery of β -cell function after partial pancreatectomy in humans. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 620-624.	3.4	22
84	GLP-1 analogues and insulin: sound the wedding bells?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 193-195.	9.6	24
85	Cell cycle control of β -cell replication in the prenatal and postnatal human pancreas. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E221-E230.	3.5	60
86	Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 2160-2168.	0.6	104
87	Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. <i>Diabetologia</i> , 2011, 54, 10-18.	6.3	402
88	Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. <i>Diabetes Care</i> , 2011, 34, 2015-2022.	8.6	479
89	GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 1270-1276.	0.6	141
90	Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2048-2053.	8.6	41

#	ARTICLE	IF	CITATIONS
91	Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans. <i>Diabetes</i> , 2011, 60, 1561-1565.	0.6	291
92	Diminished glucagon suppression after β -cell reduction is due to impaired α -cell function rather than an expansion of α -cell mass. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E717-E723.	3.5	30
93	Determinants of glucose control in patients with chronic pancreatitis. <i>Diabetologia</i> , 2010, 53, 1062-1069.	6.3	36
94	Endogenous hyperinsulinaemia in insulinoma patients is not associated with changes in beta-cell area and turnover in the tumor-adjacent pancreas. <i>Regulatory Peptides</i> , 2010, 165, 180-185.	1.9	3
95	Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β -Cell Function?. <i>Diabetes</i> , 2010, 59, 1117-1125.	0.6	189
96	Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β -cell area. <i>European Journal of Endocrinology</i> , 2010, 163, 551-558.	3.7	17
97	β -cell development and turnover during prenatal life in humans. <i>European Journal of Endocrinology</i> , 2010, 162, 559-568.	3.7	85
98	Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4061-4065.	3.6	6
99	Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. <i>Regulatory Peptides</i> , 2010, 160, 75-80.	1.9	97
100	Validation of different replication markers for the detection of beta-cell proliferation in human pancreatic tissue. <i>Regulatory Peptides</i> , 2010, 162, 115-121.	1.9	19
101	Individualised incretin-based treatment for type 2 diabetes. <i>Lancet, The</i> , 2010, 376, 393-394.	13.7	14
102	Waking up the gut in critically ill patients. <i>Critical Care</i> , 2010, 14, 183.	5.8	4
103	Insulin Secretion. , 2010, , 624-635.		0
104	Linking the Genetics of Type 2 Diabetes With Low Birth Weight: A Role for Prenatal Islet Maldevelopment?. <i>Diabetes</i> , 2009, 58, 1255-1256.	0.6	31
105	Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1379-1385.	3.6	51
106	Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2857-2863.	3.6	27
107	Metabolic consequences of a 50% partial pancreatectomy in humans. <i>Diabetologia</i> , 2009, 52, 306-317.	6.3	77
108	Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 213-222.	4.4	43

#	ARTICLE	IF	CITATIONS
109	The contribution of incretin hormones to the pathogenesis of type 2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 433-441.	4.7	31
110	Reduced Pancreatic Volume and β -Cell Area in Patients With Chronic Pancreatitis. <i>Gastroenterology</i> , 2009, 136, 513-522.	1.3	93
111	Functional Assessment of Pancreatic β -Cell Area in Humans. <i>Diabetes</i> , 2009, 58, 1595-1603.	0.6	147
112	Amino Acid Malnutrition in Patients With Chronic Pancreatitis and Pancreatic Carcinoma. <i>Pancreas</i> , 2009, 38, 416-421.	1.1	47
113	Beta cell mass in diabetes: a realistic therapeutic target?. <i>Diabetologia</i> , 2008, 51, 703-713.	6.3	141
114	Partial Pancreatectomy in Adult Humans Does Not Provoke β -Cell Regeneration. <i>Diabetes</i> , 2008, 57, 142-149.	0.6	152
115	β -Cell Replication Is the Primary Mechanism Subservicing the Postnatal Expansion of β -Cell Mass in Humans. <i>Diabetes</i> , 2008, 57, 1584-1594.	0.6	616
116	Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 606-607.	2.8	39
117	Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. <i>Diabetes</i> , 2008, 57, 678-687.	0.6	307
118	Orlistat Inhibition of Intestinal Lipase Acutely Increases Appetite and Attenuates Postprandial Glucagon-Like Peptide-1-(7-36)-Amide-1, Cholecystokinin, and Peptide YY Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3995-3998.	3.6	77
119	Incretins and Regulation of Insulin Secretion. , 2008, , 335-378.		4
120	Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E849-E856.	3.5	65
121	Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. <i>Regulatory Peptides</i> , 2007, 143, 64-68.	1.9	70
122	The replication of β cells in normal physiology, in disease and for therapy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 758-768.	2.8	238
123	Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type 2 diabetes. <i>Clinical Anatomy</i> , 2007, 20, 933-942.	2.7	378
124	Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. <i>Diabetologia</i> , 2007, 50, 806-813.	6.3	75
125	Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis. <i>Diabetologia</i> , 2007, 50, 2323-2331.	6.3	116
126	The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. <i>Diabetologia</i> , 2007, 50, 2413-2416.	6.3	19

#	ARTICLE	IF	CITATIONS
127	The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	1
128	Intrahepatic Transplanted Islets in Humans Secrete Insulin in a Coordinate Pulsatile Manner Directly Into the Liver. <i>Diabetes</i> , 2006, 55, 2324-2332.	0.6	36
129	Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. <i>Gastroenterology</i> , 2006, 130, 44-54.	1.3	218
130	Glucagon-like peptide 2 inhibits ghrelin secretion in humans. <i>Regulatory Peptides</i> , 2006, 137, 173-178.	1.9	15
131	Postprandial Suppression of Glucagon Secretion Depends on Intact Pulsatile Insulin Secretion: Further Evidence for the Intraislet Insulin Hypothesis. <i>Diabetes</i> , 2006, 55, 1051-1056.	0.6	128
132	Increased vulnerability of newly forming beta cells to cytokine-induced cell death. <i>Diabetologia</i> , 2006, 49, 83-89.	6.3	53
133	Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. <i>Diabetologia</i> , 2006, 49, 452-458.	6.3	244
134	Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. <i>Diabetologia</i> , 2006, 49, 1838-1844.	6.3	177
135	Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. <i>Diabetologia</i> , 2006, 49, 2689-2696.	6.3	62
136	Response to comment on: Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC (2006) Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. <i>Diabetologia</i> 49:1838-1844. <i>Diabetologia</i> , 2006, 49, 2803-2804.	6.3	7
137	Incretins and the development of type 2 diabetes. <i>Current Diabetes Reports</i> , 2006, 6, 194-201.	4.2	81
138	The Potential for Stem Cell Therapy in Diabetes. <i>Pediatric Research</i> , 2006, 59, 65R-73R.	2.3	50
139	The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.	3.5	90
140	Hyperinsulinemic Hypoglycemia After Gastric Bypass Surgery Is Not Accompanied by Islet Hyperplasia or Increased A-Cell Turnover. <i>Diabetes Care</i> , 2006, 29, 1554-1559.	8.6	234
141	Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. <i>World Journal of Gastroenterology</i> , 2006, 12, 1874.	3.3	8
142	Glucagon-like peptide 1 (GLP-1) in biology and pathology. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 91-117.	4.0	250
143	Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. <i>Diabetologia</i> , 2005, 48, 1872-1881.	6.3	72
144	Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?. <i>Diabetologia</i> , 2005, 48, 2221-2228.	6.3	441

#	ARTICLE	IF	CITATIONS
145	GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2005, 5, 485-497.	0.2	3
146	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. <i>Diabetes</i> , 2005, 54, 2212-2218.	0.6	113
147	Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). <i>Diabetes Care</i> , 2005, 28, 2551-2553.	8.6	73
148	Pulsatile Insulin Secretion Dictates Systemic Insulin Delivery by Regulating Hepatic Insulin Extraction In Humans. <i>Diabetes</i> , 2005, 54, 1649-1656.	0.6	201
149	Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. <i>Regulatory Peptides</i> , 2005, 128, 135-148.	1.9	160
150	GIP as a Potential Therapeutic Agent?. <i>Hormone and Metabolic Research</i> , 2004, 36, 859-866.	1.5	42
151	Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, S220-S224.	0.6	73
152	Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, S190-S196.	0.6	177
153	Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, 654-662.	0.6	277
154	Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. <i>British Heart Journal</i> , 2004, 90, 9-12.	2.1	96
155	Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 587-606.	4.7	52
156	Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2004, 122, 209-217.	1.9	105
157	Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. <i>Critical Care Medicine</i> , 2004, 32, 848-851.	0.9	87
158	Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E621-E625.	3.5	117
159	The potential role of glucagon-like peptide 1 in diabetes. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 402-10.	2.3	26
160	Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. <i>Diabetologia</i> , 2003, 46, 798-801.	6.3	270
161	Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2719-2725.	3.6	315
162	Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1579-1585.	3.4	43

#	ARTICLE	IF	CITATIONS
163	The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). <i>Regulatory Peptides</i> , 2003, 113, 95-100.	1.9	18
164	Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide. <i>BioDrugs</i> , 2003, 17, 93-102.	4.6	52
165	Combined Pancreas and Kidney Transplantation in a Lean Type 2 Diabetic Patient. Effects on Insulin Secretion and Sensitivity. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 420-424.	1.2	27
166	Gastric Inhibitory Polypeptide: the neglected incretin revisited. <i>Regulatory Peptides</i> , 2002, 107, 1-13.	1.9	197
167	Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. <i>European Journal of Pharmacology</i> , 2002, 440, 269-279.	3.5	115
168	Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes</i> , 2001, 50, 2497-2504.	0.6	206
169	Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3575-3581.	3.6	344